Literature DB >> 12557298

Oculobulbar involvement is typical with Lambert-Eaton myasthenic syndrome.

Ted M Burns1, James A Russell, Daniel H LaChance, H Royden Jones.   

Abstract

Oculobulbar symptoms and/or signs were present in 18 of 23 (78%) of Lambert-Eaton myasthenic syndrome (LEMS) patients evaluated at the Lahey Clinic (Table). Sixty-five percent (15 of 23) of our patients had ptosis and/or diplopia, each present in 11 individuals. Bulbar signs and symptoms, including dysarthria in 10 and dysphagia in 8 patients, also were observed among our LEMS population. More than one prereferral oculobulbar feature occurred in 13 of our LEMS patients. Prereferral diagnostic considerations included myasthenia gravis, myopathies, and psychiatric disorders. These findings suggest that these atypical characteristics served to dissuade some colleagues from a diagnosis of LEMS. Thus, the presence of oculobulbar symptoms and signs cannot be used to exclude LEMS from the differential diagnosis.

Entities:  

Mesh:

Year:  2003        PMID: 12557298     DOI: 10.1002/ana.10477

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  4 in total

1.  Dysphagia caused by ptosis.

Authors:  Koichi Tsunoda; Hiroko Satoh; Yoko Morita
Journal:  BMJ Case Rep       Date:  2009-02-16

2.  Nonregional small fibre neuropathy in cases of autoimmune autonomic neuropathy.

Authors:  Andrea Maier; Romina Kapfenberger; Istvan Katona; Joachim Weis; Jörg B Schulz; Roman Rolke
Journal:  J Neurol       Date:  2022-09-09       Impact factor: 6.682

Review 3.  Lambert-Eaton Myasthenic syndrome: early diagnosis is key.

Authors:  Trajche Ivanovski; Francesc Miralles
Journal:  Degener Neurol Neuromuscul Dis       Date:  2019-05-13

4.  Ophthalmoplegia associated with lung adenocarcinoma in a patient with the Lambert-Eaton myasthenic syndrome: A case report.

Authors:  Yufeng Tang; Ke Wang; Zhonglun Chen; Muke Zhou; Jingfeng Duan; Tao Liu; Dong Zhou
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.